Drug Recall: Simvastatin 5 mg tablets due to manufacturing compliance violations
Direct Rx is recalling 51 bottles of Simvastatin 5 mg tablets nationwide due to Good Manufacturing Practice deviations. The recall is voluntary and was initiated in March 2023.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is a Class II recall for manufacturing compliance violations with no reported illnesses or injuries. The rubric classifies voluntary precautionary recalls without reported harm as Moderate (score 2).
Plain-English summary
Direct Rx is recalling Simvastatin, USP, 5 mg tablets in 90-count bottles with National Drug Code (NDC) 61919-0710-90 due to Good Manufacturing Practice (cGMP) deviations. The recall affects 51 bottles that were distributed nationwide in the United States.
The affected lot numbers are 03JA2209, 28FE2225, 28AP2211, and 07AP2203, with an expiration date of June 30, 2023. The FDA classified this as a Class II recall on March 24, 2023. The recall was initiated by Direct Rx on March 13, 2023, on a voluntary basis and was terminated on June 17, 2024.
The recalled product
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (6)
- Lot
- expiry: 03JA2209
- 28FE2225
- 28AP2211
- 07AP2203
- exp 6/30/23
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 11 recalled by Direct Rx under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 11 products in this recall →Related recalls
Same manufacturer · Direct Rx
See all →- ModerateDuloxetine 30 mg capsules recalled for impurity above FDA limits
FDA (Drugs) · 2026-07-01
- HighDuloxetine delayed-release capsules exceed the interim nitrosamine impurity limit
FDA (Drugs) · 2025-08-13
- HighDirect Rx duloxetine 30 mg capsules exceed the interim nitrosamine limit
FDA (Drugs) · 2025-08-13
- ModerateCiprofloxacin Ophthalmic Solution Recalled for Defective Container Cap
FDA (Drugs) · 2025-04-23
- HighGeneric Ibuprofen 800mg Recalled Due to Failed Impurity and Degradation Specifications
FDA (Drugs) · 2024-11-13
Same hazard · manufacturing defect
See all →- HighBeak & Skiff Alcohol Antiseptic Sanitizer recalled for acetaldehyde contamination
FDA (Drugs) · 2026-09-09
- HighSun Pharmaceutical Recalls Carbamazepine Tablets Due to Manufacturing Deviations
FDA (Drugs) · 2026-08-26
- HighU2 Total Knee System Femoral Valgus Adaptor Recall
FDA (Devices) · 2026-08-12
- HighKnee Prosthesis Trial Recall for Manufacturing Defect
FDA (Devices) · 2026-08-12
- HighUnited Orthopedic Corp. Recalls Femoral Valgus Offset Adaptors for U2 Total Knee System
FDA (Devices) · 2026-08-12